Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328112747> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W4328112747 endingPage "100877" @default.
- W4328112747 startingPage "100877" @default.
- W4328112747 abstract "Although introduction of immune checkpoint inhibitors has revolutionized the treatment of cancer, their response rates are generally low. Preclinical and early phase clinical data suggest that MEK inhibition may sensitize tumors to immune checkpoint inhibitors by upregulating tumor antigen expression, programmed death-ligand 1 (PD-L1) expression, and tumor T-cell infiltration. We evaluated the efficacy and safety of cobimetinib plus atezolizumab in patients with advanced solid tumors in the open-label, multicohort phase II COTEST study.This analysis of the COTEST trial included patients from cohorts 1-4 [1-3: anti-programmed cell death protein 1 (PD-1)/PD-L1 treatment-naive patients; 4: patients with disease progression on anti-PD-1/anti-PD-L1 treatment] who received cobimetinib 60 mg once daily for the first 21 days and intravenous infusions of atezolizumab 840 mg on days 1 and 15 of each 28-day cycle. Efficacy endpoints included objective response rate, overall survival, progression-free survival (PFS), and disease control rate.Overall, 77 patients were enrolled in cohorts 1-4 (78% male; median age 62.8 years). Objective response rate was 20% in cohort 1 [squamous cell carcinoma of the head and neck (SCCHN)], 30% in cohort 2 (urothelial carcinoma), and 18% in cohort 3 (renal cell carcinoma); there were no responders among 20 patients in cohort 4 (SCCHN). The disease control rates in cohorts 1-4 were 50%, 40%, 24%, and 25%, respectively. The median PFS was 5.5, 3.4, 3.4, and 3.6 months in cohorts 1-4, respectively, and the median overall survival was 16.8, 18.7, 21.7, and 7.7 months, respectively. Most adverse events were of grade 1/2 and were manageable.Cobimetinib plus atezolizumab had moderate activity in patients with anti-PD-1/PD-L1 treatment-naive SCCHN and urothelial carcinoma, and weak activity in anti-PD-1/PD-L1 treatment-naive renal cell carcinoma, and no activity in checkpoint inhibitor-treated patients." @default.
- W4328112747 created "2023-03-22" @default.
- W4328112747 creator A5002841085 @default.
- W4328112747 creator A5013642240 @default.
- W4328112747 creator A5028388168 @default.
- W4328112747 creator A5034906272 @default.
- W4328112747 creator A5042401127 @default.
- W4328112747 creator A5047234703 @default.
- W4328112747 creator A5050390394 @default.
- W4328112747 creator A5061365371 @default.
- W4328112747 creator A5069448782 @default.
- W4328112747 creator A5071949663 @default.
- W4328112747 creator A5072911394 @default.
- W4328112747 creator A5072978374 @default.
- W4328112747 date "2023-04-01" @default.
- W4328112747 modified "2023-09-27" @default.
- W4328112747 title "Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study" @default.
- W4328112747 cites W1933761723 @default.
- W4328112747 cites W2094481139 @default.
- W4328112747 cites W2124427232 @default.
- W4328112747 cites W2237254160 @default.
- W4328112747 cites W2289851792 @default.
- W4328112747 cites W2474527756 @default.
- W4328112747 cites W2529484692 @default.
- W4328112747 cites W2560367415 @default.
- W4328112747 cites W2777192533 @default.
- W4328112747 cites W2791483720 @default.
- W4328112747 cites W2929513598 @default.
- W4328112747 cites W2938353934 @default.
- W4328112747 cites W2938645074 @default.
- W4328112747 cites W2986633517 @default.
- W4328112747 cites W3010839046 @default.
- W4328112747 cites W3113132520 @default.
- W4328112747 cites W3129646946 @default.
- W4328112747 cites W3137422569 @default.
- W4328112747 doi "https://doi.org/10.1016/j.esmoop.2023.100877" @default.
- W4328112747 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36947985" @default.
- W4328112747 hasPublicationYear "2023" @default.
- W4328112747 type Work @default.
- W4328112747 citedByCount "3" @default.
- W4328112747 countsByYear W43281127472023 @default.
- W4328112747 crossrefType "journal-article" @default.
- W4328112747 hasAuthorship W4328112747A5002841085 @default.
- W4328112747 hasAuthorship W4328112747A5013642240 @default.
- W4328112747 hasAuthorship W4328112747A5028388168 @default.
- W4328112747 hasAuthorship W4328112747A5034906272 @default.
- W4328112747 hasAuthorship W4328112747A5042401127 @default.
- W4328112747 hasAuthorship W4328112747A5047234703 @default.
- W4328112747 hasAuthorship W4328112747A5050390394 @default.
- W4328112747 hasAuthorship W4328112747A5061365371 @default.
- W4328112747 hasAuthorship W4328112747A5069448782 @default.
- W4328112747 hasAuthorship W4328112747A5071949663 @default.
- W4328112747 hasAuthorship W4328112747A5072911394 @default.
- W4328112747 hasAuthorship W4328112747A5072978374 @default.
- W4328112747 hasBestOaLocation W43281127471 @default.
- W4328112747 hasConcept C121608353 @default.
- W4328112747 hasConcept C126322002 @default.
- W4328112747 hasConcept C143998085 @default.
- W4328112747 hasConcept C2775949291 @default.
- W4328112747 hasConcept C2777701055 @default.
- W4328112747 hasConcept C2780057760 @default.
- W4328112747 hasConcept C71924100 @default.
- W4328112747 hasConcept C72563966 @default.
- W4328112747 hasConcept C90924648 @default.
- W4328112747 hasConceptScore W4328112747C121608353 @default.
- W4328112747 hasConceptScore W4328112747C126322002 @default.
- W4328112747 hasConceptScore W4328112747C143998085 @default.
- W4328112747 hasConceptScore W4328112747C2775949291 @default.
- W4328112747 hasConceptScore W4328112747C2777701055 @default.
- W4328112747 hasConceptScore W4328112747C2780057760 @default.
- W4328112747 hasConceptScore W4328112747C71924100 @default.
- W4328112747 hasConceptScore W4328112747C72563966 @default.
- W4328112747 hasConceptScore W4328112747C90924648 @default.
- W4328112747 hasFunder F4320307779 @default.
- W4328112747 hasFunder F4320309432 @default.
- W4328112747 hasIssue "2" @default.
- W4328112747 hasLocation W43281127471 @default.
- W4328112747 hasLocation W43281127472 @default.
- W4328112747 hasLocation W43281127473 @default.
- W4328112747 hasOpenAccess W4328112747 @default.
- W4328112747 hasPrimaryLocation W43281127471 @default.
- W4328112747 hasRelatedWork W2315085516 @default.
- W4328112747 hasRelatedWork W2516175431 @default.
- W4328112747 hasRelatedWork W2598135683 @default.
- W4328112747 hasRelatedWork W2603773853 @default.
- W4328112747 hasRelatedWork W2785808209 @default.
- W4328112747 hasRelatedWork W3215044659 @default.
- W4328112747 hasRelatedWork W4280643539 @default.
- W4328112747 hasRelatedWork W4288703684 @default.
- W4328112747 hasRelatedWork W4289517314 @default.
- W4328112747 hasRelatedWork W4320915119 @default.
- W4328112747 hasVolume "8" @default.
- W4328112747 isParatext "false" @default.
- W4328112747 isRetracted "false" @default.
- W4328112747 workType "article" @default.